A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).

Timeline

Start

2026-04-13

Primary completion

2029-04-30

Completion

2029-04-30

Drugs

Indications